Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Hikma Pharmaceuticals plc
Industry Sector: HealthTechnology
CEO: Riad Mishlawi
Number Of Employees: 9,500
Enterprise Value: $6,698,608,102
PE Ratio: 13.94
Exchange/Ticker 1: LSE:HIK
Exchange/Ticker 2: N/A
Latest Market Cap: $5,037,996,933
BioCentury | Oct 24, 2024
Data Byte
New modalities flood the EGFR pipeline
Bispecifics, ADCs and more compete to become the next-generation of EGFR-targeting agents
BioCentury | Jun 18, 2024
Deals
Deals Report: Syncona merging Freeline, SwanBio to form Spur
Plus: AbbVie licenses TL1A mAb from FutureGen for IBD, and updates from Takeda, Ascentage, Pfizer, ProFound and more
BioCentury | Mar 8, 2024
Finance
Trio of large, crossover-backed rounds lead week’s deals
Alumis raises $259M, Sionna $182M to pursue big opportunities in immunology, cystic fibrosis. Mammen’s FogPharma raises $145M
BioCentury | Oct 12, 2022
Management Tracks
Wiggins, Simon join C-suite at Vaxcyte
Plus AZ’s Sheldon joining GSK (at last) and updates from Sudo, Walden, 1910 and more
BioCentury | Jun 21, 2021
Product Development
June 21 Quick Takes: NIH adds GSK- Vir mAb to COVID-19 treatment guidelines; plus Theravance, WHO, Tarsus and Amarin
NIH updated its COVID-19 treatment guidelines to recommend sotrovimab (VIR-7831) from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Vir Biotechnology Inc. (NASDAQ:VIR) to treat high-risk outpatients
BioCentury | May 1, 2021
Regulation
April 30 Quick Takes: Bilenker has $212M to build newco Treeline’s toolbox; plus Farxiga, Opdivo, BioCryst, Leo, Hikma and more
An SEC filing released Friday revealed that Josh Bilenker and Jeffrey Engelman have $212 million to begin building newly launched Treeline Biosciences Inc.’s toolbox for chasing validated but
BioCentury | Sep 5, 2020
Product Development
Sept. 4 Quick Takes: HiFiBiO in second cancer deal with Gilead; plus Bridgewest-Pfizer, Amarin, Intercept, Santhera-Idorsia, CMS, Ascendis
Gilead, HiFiBiO partner on AMLHiFiBiO Therapeutics has closed its second partnership with the Kite Pharma Inc. unit of Gilead Sciences Inc. (NASDAQ:GILD), this time using its antibody and single-cell
BioCentury | Mar 31, 2020
Product Development
Amarin set to appeal patent ruling that points way to generic competition for Vascepa
BioCentury | Jan 25, 2019
Politics, Policy & Law
101 problems with patent eligibility
Why diagnostic innovation needs Congress to fix patent law’s Section 101
Items per page:
1 - 10 of 66